IL2

IL2 Full Name

Interleukin 2

IL2 Introduction

Interleukin-2 (IL-2) is a central immunoregulatory cytokine that sits at the crossroads of immune activation and immune tolerance, making it both a powerful therapeutic target and a persistent challenge for drug developers. Originally identified as a T-cell growth factor, IL-2 is rapidly produced by activated CD4⁺ T cells and signals through a heterotrimeric receptor composed of CD25 (IL-2Rα), CD122 (IL-2Rβ), and CD132 (common γ chain). For researchers struggling with the limitations of classical IL-2 protein therapy—such as high manufacturing costs, short half-life, and severe systemic toxicity—recent advances in small-molecule screening and protein engineering have opened new paths. Notably, DNA-encoded library (DEL) approaches have enabled the discovery of non-antibody small molecules that directly bind IL-2, including ligands capable of competing with CD25. These findings highlight IL-2 not only as a cytokine to be supplemented, but as a druggable protein whose interactions can be finely tuned to reshape immune responses.

Functionally, IL-2 plays a dual and often paradoxical role in the immune system, which is a major pain point for translational researchers. On one hand, IL-2 is essential for the expansion and cytotoxic function of effector T cells (Teff) and natural killer (NK) cells, underpinning its long-standing use in cancer immunotherapy. On the other hand, IL-2 is indispensable for the survival and suppressive activity of regulatory T cells (Tregs), which can blunt anti-tumor immunity and promote immune tolerance. This functional bifurcation is tightly controlled at both the receptor level and the gene regulation level. Recent chromatin-level studies have revealed that IL2 expression is governed by long-range cis-regulatory elements located tens to hundreds of kilobases away from the gene itself, some of which harbor autoimmune disease–associated variants. These insights help explain why dysregulated IL-2 signaling contributes to immune imbalance even when the IL2 coding sequence remains intact, and they offer new genomic targets for modulating IL-2 output with greater precision.

Clinically, IL-2 is deeply implicated in cancer, autoimmunity, and inflammatory diseases, but its therapeutic window has historically been narrow. High-dose IL-2 can induce durable responses in a subset of cancer patients, yet its use is limited by vascular leak syndrome and systemic inflammation. To address these issues, next-generation IL-2 strategies have emerged, including engineered IL-2 variants, antibody–cytokine fusion proteins, and multi-cytokine constructs designed to bias signaling toward specific immune cell subsets. Engineered IL-2/antibody complexes have demonstrated the ability to preferentially expand effector or memory T cells while sparing Tregs, whereas tumor-targeted IL-2–based fusion proteins, such as IL-2 combined with TNF, show enhanced anti-tumor efficacy through T-cell–dependent mechanisms. Together, these advances position IL-2 as a highly versatile but technically demanding target, where success depends on precise control of molecular interactions, gene regulation, and immune context—exactly the challenges that modern immuno-oncology and immune engineering aim to solve.

Alternate Names for IL2

IL2; interleukin 2; IL-2; TCGF; lymphokine; interleukin-2; aldesleukin; T cell growth factor; involved in regulation of T-cell clonal expansion

• 1.Fabian KP, et al.; PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020, 8(1):e000450.
  2.Mehra P, Wells AD. Long-Range Transcriptional Control of the Il2 Gene by an Intergenic Enhancer. Mol Cell Biol. 2015, 35(22):3880-91.